These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16179790)

  • 1. Effects of recombinant human thyrotropin on heart rate variability and blood pressure in patients on l-thyroxine-suppressive therapy for differentiated thyroid carcinoma.
    Murialdo G; Casu M; Cappi C; Patrone V; Repetto E; Copello F; Minuto F; Giusti M
    Horm Res; 2005; 64(2):100-6. PubMed ID: 16179790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sympatho-vagal control of heart rate variability in patients treated with suppressive doses of L-thyroxine for thyroid cancer.
    Casu M; Cappi C; Patrone V; Repetto E; Giusti M; Minuto F; Murialdo G
    Eur J Endocrinol; 2005 Jun; 152(6):819-24. PubMed ID: 15941920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
    Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
    J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperthyroidism is characterized by both increased sympathetic and decreased vagal modulation of heart rate: evidence from spectral analysis of heart rate variability.
    Chen JL; Chiu HW; Tseng YJ; Chu WC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):611-6. PubMed ID: 16712661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer.
    Kovatcheva RD; Hadjieva TD; Kirilov GG; Lozanov BS
    Nucl Med Rev Cent East Eur; 2004; 7(1):13-9. PubMed ID: 15318305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Human Thyrotropin Improves Endothelial Coronary Flow Reserve in Thyroidectomized Patients with Differentiated Thyroid Cancer.
    Ippolito S; Ippolito R; Peirce C; Esposito R; Arpaia D; Santoro C; Pontieri G; Cocozza S; Galderisi M; Biondi B
    Thyroid; 2016 Nov; 26(11):1528-1534. PubMed ID: 27558484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of thyrotropin suppressive therapy on heart rate variability and QT dispersion in patients with differentiated thyroid cancer.
    Liu C; Lv H; Li Q; Fu S; Tan J; Wang C; Wang X; Ma Y
    Medicine (Baltimore); 2020 Jul; 99(28):e21190. PubMed ID: 32664162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer.
    Montesano T; Durante C; Attard M; Crocetti U; Meringolo D; Bruno R; Tumino S; Rubello D; Al-Nahhas A; Colandrea M; Maranghi M; Travascio L; Ronga G; Torlontano M
    Biomed Pharmacother; 2007 Sep; 61(8):468-71. PubMed ID: 17553654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early detection of isolated left ventricular diastolic dysfunction in high-risk differentiated thyroid carcinoma patients on TSH-suppressive therapy.
    Taillard V; Sardinoux M; Oudot C; Fesler P; Rugale C; Raingeard I; Renard E; Ribstein J; du Cailar G
    Clin Endocrinol (Oxf); 2011 Nov; 75(5):709-14. PubMed ID: 21645022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Response of thyroglobulin, anti-thyroglobulin antibodies, TSH, FT4 and total T3 after rhTSH stimulation in differentiated thyroid carcinoma].
    Moreno Ortega E; Vallejo Casas JA; Mena Bares LM; del Real Núñez R; Maza Muret FR; Hidalgo Ramos FJ; Latre Romero JM
    Rev Esp Med Nucl; 2008; 27(4):253-8. PubMed ID: 18682151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of recombinant human TSH on the uptake of radioactive iodine ((123)I) by the thyroid gland in healthy beagles.
    Campos M; Peremans K; Duchateau L; Dobbeleir A; Vandermeulen E; van Hoek I; Paes G; Daminet S
    Domest Anim Endocrinol; 2010 Nov; 39(4):215-21. PubMed ID: 20688462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
    Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sympathovagal imbalance in thyroid dysfunctions in females: correlation with thyroid profile, heart rate and blood pressure.
    Karthik S; Pal GK; Nanda N; Hamide A; Bobby Z; Amudharaj D; Pal P
    Indian J Physiol Pharmacol; 2009; 53(3):243-52. PubMed ID: 20329371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
    Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.
    Verburg FA; Smit JW; Grelle I; Visser TJ; Peeters RP; Reiners C
    Clin Endocrinol (Oxf); 2012 Apr; 76(4):577-81. PubMed ID: 22017394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma.
    Pitoia F; Tamer EE; Schere DB; Passerieu M; Bruno OD; Niepomniszcze H
    Medicina (B Aires); 2006; 66(2):125-30. PubMed ID: 16715760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [L-thyroxine therapy in differentiated thyroid carcinoma: criteria for evaluation of TSH suppression].
    Kowalczyk P; Roskosz J; Jurecka-Tuleja B; Gubała E; Czernik E; Jarzab B
    Wiad Lek; 2001; 54(5-6):268-76. PubMed ID: 11556209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.